Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Walter Erich Aulitzky"'
Autor:
Annika Nelde, Yacine Maringer, Tatjana Bilich, Helmut R. Salih, Malte Roerden, Jonas S. Heitmann, Ana Marcu, Jens Bauer, Marian C. Neidert, Claudio Denzlinger, Gerald Illerhaus, Walter Erich Aulitzky, Hans-Georg Rammensee, Juliane S. Walz
Publikováno v:
Frontiers in Immunology, Vol 12 (2021)
Antigen-specific immunotherapies, in particular peptide vaccines, depend on the recognition of naturally presented antigens derived from mutated and unmutated gene products on human leukocyte antigens, and represent a promising low-side-effect concep
Externí odkaz:
https://doaj.org/article/fce84625805140c6b8f41a79e36f3544
Autor:
Tobias Benjamin Beigl, Sandra Weller, Benjamin Schäfer, Walter Erich Aulitzky, Hans-Georg Kopp, Markus Rehm, Frank Essmann
Publikováno v:
Cancer Research. 82:3704-3704
Apoptosis is a complex and highly regulated cellular suicide program culminating in a caspase-dependent self-destruction. As a critical step of intrinsic apoptosis, pro-apoptotic effector Bcl-2 proteins BAX, BAK and BOK form pores in the mitochondria
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::acec9a208927e1840e77810b98829dce
https://doi.org/10.1158/1538-7445.am2022-3704
https://doi.org/10.1158/1538-7445.am2022-3704
Autor:
Michael Pfreundschuh, Wolf-Dieter Ludwig, Lorenz Trümper, Orhan Sezer, Andreas Lohri, Martin Wilhelm, Jeremy Franklin, Markus W. Löffler, Dirk Hasenclever, Andreas Engert, Walter-Erich Aulitzky, Mathias Hänel, Hans Konrad Müller-Hermelink, Mathias J. Rummel, Bernd Dörken, Volker Diehl, Peter Koch, Martin Bentz
Publikováno v:
Journal of Clinical Oncology. 27:4548-4554
Purpose The HD9 trial of the German Hodgkin Study Group compared two different doses (baseline and escalated) of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP) chemotherapy regimen in 1,19
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::304529dee0bf39ec2d2080822eb0d932
https://doi.org/10.1200/jco.2008.19.8820
https://doi.org/10.1200/jco.2008.19.8820
Autor:
Holger Schulz, Wolfgang-Ulrich Knauf, Michael Hallek, Dieter Huhn, Andreas Engert, Saskia K. Klein, Walter-Erich Aulitzky, Marcel Reiser, Volker Diehl, Manfred Hensel, Ute Rehwald, Axel Hinke, Michael Herold
Publikováno v:
Blood. 100:3115-3120
This multicenter phase 2 trial investigated safety and efficacy of a new immunochemotherapeutic regimen combining rituximab (R) and fludarabine (F) in patients with fludarabine- and anthracycline-naive chronic lymphocytic leukemia (CLL). The rational
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4fb367a578755c633d99e753ece77ae6
https://doi.org/10.1182/blood-2002-03-0972
https://doi.org/10.1182/blood-2002-03-0972